image: Professor Robert T. Schooley to Deliver Keynote at the 8th World Congress on Targeting Phage Therapy 2025
Credit: @phagetherapy-site.com
It is a great pleasure to announce that Professor Robert T. Schooley, from the University of California, San Diego (USA), will be a keynote speaker at the 8th World Congress on Targeting Phage Therapy, scheduled for June 10-11, 2025, in Berlin.
Professor Schooley will present a talk titled “Phage Therapy 2030: Getting from Here to There” In this address, he will explore the accelerating integration of phages into clinical medicine over the past decade and discuss the necessary steps to ensure widespread adoption and advancements in phage therapy by 2030.
As an infectious disease specialist, Professor Schooley’s expertise spans HIV, hepatitis C (HCV), influenza, and global health. He was among the first researchers to describe the humoral and cellular immune responses to HIV infection and has played a pivotal role in advancing phage therapy applications for antimicrobial resistance (AMR).
Currently, Professor Schooley serves as a Professor in the Division of Infectious Diseases within the Department of Medicine at UC San Diego School of Medicine, where he leads a multidisciplinary research program focused on hepatitis C and novel infectious disease treatments.
The 8th World Congress on Targeting Phage Therapy will gather leading scientists, clinicians, industry experts, and innovators to explore the latest advances, challenges, and clinical applications of bacteriophage therapy, shaping the future of phage-based medicine.
Featured Speakers – 8th World Congress on Targeting Phage Therapy (2025)
1. Professor Robert T. Schooley (USA) – “Phage Therapy 2030: Getting from Here to There”
2. Stan J.J. Brouns (Netherlands) – “The Clinical Relevance of Bacteriophage Resistance: Mechanisms and Challenges for Phage Therapy”
3. Barbara Brenner (Germany) – “Phage Therapy in Europe: Legal, Regulatory, and Ethical Issues”
4. Franklin Nobrega (UK) – “KlebPhaCol: Novel Gut Phage Order Associated with the Human Gut”
5. Alena Kaltenbrunner (Italy) – “Engineering Phages for Cancer Therapy: Insights into Immune Interactions and Targeting in Ex-Vivo and In-Vivo Models”
6. Domenico Frezza (Italy) – “Optimizing the Phage-Bacteria Ratio for Phage Therapy: Metagenomic Insights into Microbial Balance and Dysbiosis”
7. Jumpei Fujiki (Japan) – “Biocontrol of Phage Resistance in Pseudomonas Infections – Fitness Trade-Offs Between Phages and Antibiotic Sensitivity”
8. Loris Rizzello (Italy) – “Phage-Inspired Strategies for Tackling Mycobacterium abscessus Infections”
9. Mikael Skurnik (Finland) – “Yersinia Phage Stories: Impact on Phage Therapy”
10. Hidetomo Iwano (Japan) – “Phage Therapy in Veterinary Medicine: Presentation of First Clinical Trial in Japan”
11. Marco Cafora (Italy) – “Ex Vivo Pig Lung as a New Cystic Fibrosis Model for the Study of Pseudomonas aeruginosa Biofilm Infection and Phage Therapy Application”
Practical Session on Phage Manufacturing & Market Entry
The 8th World Congress on Targeting Phage Therapy 2025 will feature a dedicated practical session on phage production, manufacturing, and commercialization. This session will provide a step-by-step guide from laboratory preparation to large-scale production and regulatory approval. Experts will cover technical, regulatory, and business challenges, ensuring attendees gain actionable insights. Key topics include Good Manufacturing Practices (GMP), quality control, scaling production, regulatory pathways, and market access strategies. Participants will learn how to navigate licensing, compliance, and import regulations for phage products.
Join us in Berlin to gain essential expertise and connect with leading experts in phage commercialization!
For more information and to register, please visit the official website:
🔗 https://phagetherapy-site.com